微创医疗（00853.HK）披露有关拟进行心律管理业务之策略性重组之最新情况，12月16日股价上涨0.3%

Core Viewpoint - MicroPort Medical (00853) is undergoing a strategic merger to enhance its cardiac and arrhythmia management business, aiming to improve operational efficiency and market penetration while entering the heart failure sector [1] Group 1: Stock Performance - As of December 16, 2025, MicroPort Medical closed at 10.05 CNY, a 0.3% increase from the previous trading day [1] - The stock opened at 10.02 CNY, reached a high of 10.16 CNY, and a low of 9.80 CNY, with a trading volume of 1.05 billion CNY [1] - The stock's 52-week high was 16.28 CNY, and the low was 5.21 CNY [1] Group 2: Merger Details - The independent shareholders of MicroPort Cardiac Rhythm Management approved the merger agreement on December 15, 2025, with completion expected around December 19, 2025 [1] - Upon completion, all issued shares of CRM Cayman will be canceled in exchange for ordinary shares of MicroPort Cardiac Rhythm Management, making CRM Cayman a wholly-owned subsidiary [1] Group 3: Strategic Goals - The merger aims to strengthen the synergy between structural heart disease and arrhythmia management businesses, integrating product lines and global channels [1] - The company plans to leverage technological advantages from both entities to enter the heart failure sector, creating a comprehensive management solution covering all causes, stages, and processes [1] Group 4: Financial Implications - The merger will eliminate approximately 260 million USD in preferred stock buyback obligations and related interest burdens, reducing the debt-to-equity ratio [1] - CRM Cayman's previously issued 128 million USD convertible bonds have been restructured into bank loans with an interest rate of 2.8%, further optimizing the debt structure [1] - Both parties are currently advancing the final steps of the merger [1]